Acasti Pharma shareholders elect directors, ratify auditor, approve exec comp at annual meeting

Proposal No. 1 – Election of Directors The following nominees were elected as directors by the votes indicated to serve until the Company’s next annual meeting of shareholders, as set forth in the Proxy Statement: Nominee Votes For % Votes For Withheld % Votes Withheld Non-Vote Vimal Kavuru 2,746,424 97.82% 61,122 2.18% 1,271,115 A. Brian Davis 2,761,502 98.36% 46,044 1.64% 1,271,115 S. George Kottayil 2,758,885 98.27% 48,662 1.73% 1,271,115 Prashant Kohli 2,758,939 98.27% 48,607 1.73% 1,271,115 Edward Neugeboren 2,759,075 98.27% 48,471 1.73% 1,271,115

Proposal No. 3 – Advisory Vote to Approve Named Executive Officer Compensation The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement was approved by the shareholders by the following vote: For % For Against % Against Abstain % Abstain Non-Vote 2,730,102 97.24% 68,055 2.42% 9,389 0.33% 1,271,115

Proposal No. 2 – Appointment of Ernst & Young LLP The proposal to appoint Ernst & Young LLP as the Company’s independent registered public accounting firm until the close of the Company’s next annual meeting shareholders and to authorize the Company’s board of directors to fix their remuneration was approved by the shareholders by the following vote: For % For Against % Against Abstain % Abstain Non-Vote 3,982,999 97.65% 81,017 1.99% 14,644 0.36% 1